<DOC>
	<DOCNO>NCT02329847</DOCNO>
	<brief_summary>The purpose study determine safety establish recommend phase 2 dose ( RP2D ) combination ibrutinib nivolumab participant chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) , follicular cell lymphoma ( FL ) diffuse large B-cell lymphoma ( DLBCL ) . Once dose optimize , combination assess Pharmacokinetics , Pharmacodynamics , preliminary efficacy , safety participant CLL/SLL , FL DLBCL participant Richter syndrome .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics Preliminary Efficacy Combination Ibrutinib With Nivolumab Participants With Hematologic Malignancies</brief_title>
	<detailed_description>This open-label study , consist Part A ( Dose Optimization Cohorts ) Part B ( Expansion Cohorts ) . Part A consist two dose optimization cohort ( cohort A1 cohort A2 ) determine RP2D combination base safety , pharmacokinetic , pharmacodynamic assessment participant relapsed/refractory CLL/SLL B-cell non-Hodgkin lymphoma ( B-NHL ) . Part B consist 3 participant population evaluate safety clinical activity ibrutinib combination nivolumab : Cohort B1 ( participant CLL/SLL del 17p del 11q ) , Cohort B2 ( participant FL ) , Cohort B3 ( participant DLBCL ) Cohort B4 ( participant Richter syndrome ) . Part A B consist Screening Period ( 28 day enrollment ) , Treatment Period Follow Period ( every 3 month death end study ) . Participants receive nivolumab intravenously ( Day 1 every cycle ) ibrutinib orally daily 14-day cycle . Efficacy primarily evaluate International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) International Working Group ( IWG ) lymphoma guideline . Participants ' safety monitor throughout study . Further exploration pharmacokinetic/pharmacodynamic biomarker information assess throughout trial .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status grade 0 , 1 , 2 Adequate bone marrow , liver , renal function define : 1 ) Absolute neutrophil count ( ANC ) great equal ( &gt; = ) 1.5* 10^9cells/litre ( L ) ; 2 ) Platelets &gt; =75 x 109cells/L without transfusion support within 7 day prior test ; 3 ) Hemoglobin &gt; = 8 gram/deciliter ( g/dL ) without transfusion support within 7 day prior test 4 ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal ( &lt; = ) 2.5 * upper limit normal ( ULN ) 5 ) Total bilirubin le ( &lt; ) 2 milligram/deciliter ( mg/dL ) 6 ) Creatinine determine serum creatinine level &lt; =1.5 * ULN calculate creatinine clearance &gt; = 50 mL/min/1.73 m^2 Histologically confirm Bcell nonHodgkin lymphoma ( BNHL ) , Chronic Lymphocytic Leukemia ( CLL ) /Small Lymphocytic Lymphoma ( SLL ) Relapsed refractory disease least 1 4 line previous systemic therapy Measurable disease ( NHL : At least 1 measurable site disease [ &gt; 1.5 centimeter [ cm ] long axis regardless short axis measurement &gt; 1.0 cm short axis regardless long axis measurement , clearly measurable 2 perpendicular dimension ] ) Cohort B1 : SLL/CLL : 1 ) Deletion short arm chromosome 17 11 q base institutional assessment 2 ) Relapsed/refractory least 1 prior systemic therapy 3 ) Active disease base IWCLL criterion Cohort B2 : 1 ) B cell follicular lymphoma Grade 1 , 2 , 3a ( WHO criteria ) 2 ) Relapsed/refractory disease &gt; = 2 line separate Progression , prior treatment ( eligible receiving ) CD20 antibody 3 ) Measurable disease ( IWG Lugano 2014 ) Cohort B3 : 1 ) Histologicallyconfirmed DLBCL 2 ) Prior standard rituximab + anthracyclin contain regimen , receive eligible consider candidate HDASCT 3 ) Measurable disease ( IWG Lugano 2014 ) Cohort B4 : 1 ) Histologicallyconfirmed Richter syndrome define transformation CLL SLL aggressive lymphoma 2 ) Previously treat least one line standard , systemic chemotherapy eligible standard therapy 3 ) At least 1 measurable site disease base Revised Response Criteria Malignant Lymphoma Prior therapy surgery ( 3 10 week depend type ) Prior BTK inhibitor anti PD1 , anti PDL1 , anti PDL2 antiCD137 , anticytotoxic Tlymphocyte associate antigen ( CTLA4 ) antibody Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month Screening , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification , congenital long QT syndrome , QT interval correct heart rate , use Fridericia formula ( QTcF ) Screening great ( &gt; ) 470 millisecond ( m ) History stroke intracranial hemorrhage within 6 month prior first dose ibrutinib Requires treatment anticoagulation warfarin equivalent vitamin K antagonists Requires treatment strong cytochrome P450 3A ( CYP3A ) inhibitor Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hematologic Neoplasms</keyword>
	<keyword>JNJ54179060</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Nivolumab</keyword>
</DOC>